Publication date: Aug 06, 2021
Importantly, a single, local injection of the vector into the tumor also led to systemic immune responses, significantly reducing the number of lung metastases. HOOKIPA’s HB-300 program for prostate cancer also uses the LCMV and PICV arenaviral backbones directed against three validated antigens for prostate cancer: PAP, PSA, and PSMA. HOOKIPA Forward Looking Statements Certain statements set forth in this press release constitute -forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. HOOKIPA’s pipeline includes ongoing clinical trials in Human Papilloma Virus 16-positive cancers and Cytomegalovirus, as well as preclinical research in prostate cancer, HIV and Hepatitis B. HOOKIPA is developing a broad pipeline of potential first-in-class arenaviral immunotherapies in oncology and infectious disease. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. HOOKIPA is evaluating its single-vector and alternating 2-vector technologies in cancer in an ongoing Phase 1/2 clinical trial with HB-201 and HB-202.
|disease||MESH||head and neck cancer|